170 related articles for article (PubMed ID: 21711113)
1. Pharmacokinetics and dosimetry of (111)In/(188)Re-labeled PEGylated liposomal drugs in two colon carcinoma-bearing mouse models.
Lin YY; Chang CH; Li JJ; Stabin MG; Chang YJ; Chen LC; Lin MH; Tseng YL; Lin WJ; Lee TW; Ting G; Chang CA; Chen FD; Wang HE
Cancer Biother Radiopharm; 2011 Jun; 26(3):373-80. PubMed ID: 21711113
[TBL] [Abstract][Full Text] [Related]
2. Tumor burden talks in cancer treatment with PEGylated liposomal drugs.
Lin YY; Kao HW; Li JJ; Hwang JJ; Tseng YL; Lin WJ; Lin MH; Ting G; Wang HE
PLoS One; 2013; 8(5):e63078. PubMed ID: 23675454
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice.
Tsai CC; Chang CH; Chen LC; Chang YJ; Lan KL; Wu YH; Hsu CW; Liu IH; Ho CL; Lee WC; Ni HC; Chang TJ; Ting G; Lee TW
Int J Nanomedicine; 2011; 6():2607-19. PubMed ID: 22114492
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of pharmacokinetics of 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model.
Lin YY; Li JJ; Chang CH; Lu YC; Hwang JJ; Tseng YL; Lin WJ; Ting G; Wang HE
Cancer Biother Radiopharm; 2009 Aug; 24(4):453-60. PubMed ID: 19694580
[TBL] [Abstract][Full Text] [Related]
5. Comparative dosimetric evaluation of nanotargeted (188)Re-(DXR)-liposome for internal radiotherapy.
Chang CH; Stabin MG; Chang YJ; Chen LC; Chen MH; Chang TJ; Lee TW; Ting G
Cancer Biother Radiopharm; 2008 Dec; 23(6):749-58. PubMed ID: 19111045
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy evaluation of 111In-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Pang VF; Liu RS; Lin WJ; Yang CS; Ting G
J Nucl Med; 2009 Dec; 50(12):2073-81. PubMed ID: 19949027
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of (188)Re-DXR-liposome in C26 colon carcinoma ascites mice model.
Chen LC; Chang CH; Yu CY; Chang YJ; Wu YH; Lee WC; Yeh CH; Lee TW; Ting G
Nucl Med Biol; 2008 Nov; 35(8):883-93. PubMed ID: 19026950
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution, pharmacokinetics and imaging of (188)Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model.
Chen LC; Chang CH; Yu CY; Chang YJ; Hsu WC; Ho CL; Yeh CH; Luo TY; Lee TW; Ting G
Nucl Med Biol; 2007 May; 34(4):415-23. PubMed ID: 17499731
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric evaluation of nanotargeted (188)Re-liposome with the MIRDOSE3 and OLINDA/EXM programs.
Chang CH; Chang YJ; Lee TW; Ting G; Chang KP
Ann Nucl Med; 2012 Jun; 26(5):419-25. PubMed ID: 22450826
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model.
Chang YJ; Chang CH; Yu CY; Chang TJ; Chen LC; Chen MH; Lee TW; Ting G
Nucl Med Biol; 2010 Jan; 37(1):95-104. PubMed ID: 20122674
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Efficacy Evaluation of Pegylated Liposome Encapsulated With Vinorelbine Plus
Chien YC; Chou YH; Wang WH; Chen JC; Chang WS; Tsai CW; Bau DT; Hwang JJ
Cancer Genomics Proteomics; 2020; 17(1):61-76. PubMed ID: 31882552
[TBL] [Abstract][Full Text] [Related]
12. Comparative therapeutic efficacy of rhenium-188 radiolabeled-liposome and 5-fluorouracil in LS-174T human colon carcinoma solid tumor xenografts.
Hsu CW; Chang YJ; Chang CH; Chen LC; Lan KL; Ting G; Lee TW
Cancer Biother Radiopharm; 2012 Oct; 27(8):481-9. PubMed ID: 23067100
[TBL] [Abstract][Full Text] [Related]
13. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the therapeutic and diagnostic effects of PEGylated liposome-embedded 188Re on human non-small cell lung cancer using an orthotopic small-animal model.
Lin LT; Chang CH; Yu HL; Liu RS; Wang HE; Chiu SJ; Chen FD; Lee TW; Lee YJ
J Nucl Med; 2014 Nov; 55(11):1864-70. PubMed ID: 25349220
[TBL] [Abstract][Full Text] [Related]
15. Correlation between radioactivity and chemotherapeutics of the (111)In-VNB-liposome in pharmacokinetics and biodistribution in rats.
Lee WC; Chang CH; Huang CM; Wu YT; Chen LC; Ho CL; Chang TJ; Lee TW; Tsai TH
Int J Nanomedicine; 2012; 7():683-92. PubMed ID: 22359447
[TBL] [Abstract][Full Text] [Related]
16. The PEGylated liposomal doxorubicin improves the delivery and therapeutic efficiency of 188Re-Liposome by modulating phagocytosis in C26 murine colon carcinoma tumor model.
Hsu WH; Liu SY; Chang YJ; Chang CH; Ting G; Lee TW
Nucl Med Biol; 2014 Oct; 41(9):765-71. PubMed ID: 25027866
[TBL] [Abstract][Full Text] [Related]
17. A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes.
El Sayed MM; Shimizu T; Abu Lila AS; Elsadek NE; Emam SE; Alaaeldin E; Kamal A; Sarhan HA; Ando H; Ishima Y; Ishida T
Int J Pharm; 2022 Mar; 615():121539. PubMed ID: 35124114
[TBL] [Abstract][Full Text] [Related]
18. Chemoradionuclide therapy with 186re-labeled liposomal doxorubicin: toxicity, dosimetry, and therapeutic response.
Soundararajan A; Bao A; Phillips WT; McManus LM; Goins BA
Cancer Biother Radiopharm; 2011 Oct; 26(5):603-14. PubMed ID: 21834653
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.
Newman MS; Colbern GT; Working PK; Engbers C; Amantea MA
Cancer Chemother Pharmacol; 1999; 43(1):1-7. PubMed ID: 9923534
[TBL] [Abstract][Full Text] [Related]
20. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
